Enzo Biochem, Inc. (NYSE:ENZ) announced today that Kevin Krenitsky, MD,
President of Enzo Clinical Labs, will present at the 27th
Annual Lab Institute ’09, sponsored by Washington G2 Reports, on
September 23, 2009 in Arlington, Virginia.
Dr. Krenitsky will present at a panel discussion entitled "Going Inside
the Boardroom: What’s the Bottom Line for Labs During a Time of
Economic, Policy and Market Flux?”
Among the meeting’s keynote speakers will be the Hon. Newt Gingrich,
former Speaker of the U.S. House of Representatives, and Rep. Pete Stark
(D-CA), Chairman, House Ways and Means Health Subcommittee.
"The focus of this key conference, which comes at a pivotal time in the
debate over health care reform, will be on the impact various proposals
will have on diagnostic testing, which, given all the advances being
made in diagnosing diseases and how treatments are gauged, will figure
importantly in the way medicine is practiced and patients treated in the
future,” said Dr. Krenitsky. "It is a welcome opportunity that a leading
independent laboratory such as Enzo Clinical Labs has been invited to be
part of this dialogue.”
Inaugurated in 1983, Lab Institute has been the foremost independent
national forum for in-depth, balanced presentations and informed
viewpoints and insights on major policy and business issues affecting
the delivery of quality diagnostic testing and related medical services.
It is a unique platform for networking among laboratory, pathology, and
hospital/health system constituencies nationwide, and is the only forum
on diagnostics where industry, government, and technology come together.
About Enzo
Enzo Biochem is engaged in the research, development, manufacture and
licensing of innovative health care products and technologies based on
molecular biology and genetic engineering techniques, and in providing
diagnostic services to the medical community. Enzo’s Life Sciences
division develops, produces and markets proprietary labeling and
detection products for gene sequencing, genetic analysis and
immunological research among others. Its catalog of over 30,000 products
serves the molecular biology, drug discovery and pathology research
markets. The Company's therapeutic division is in various stages of
clinical evaluation of its proprietary immune regulation medicines for
uveitis and Crohn's disease and conducts pre-clinical research on
several candidate compounds aimed at producing new mineral and organic
bone, including technology that could provide therapy for osteoporosis
and fractures, among other applications. Enzo’s Clinical Labs division
provides routine and esoteric reference laboratory services for
physicians in the New York Metropolitan and New Jersey areas.
Underpinning the Company’s technology and operations is an extensive
intellectual property estate in which Enzo owns or licenses over 240
patents worldwide, and has pending applications for over 200 more. For
more information visit our website www.enzo.com.
Except for historical information, the matters discussed in this news
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that could
materially affect actual results. The Company disclaims any obligations
to update any forward-looking statement as a result of developments
occurring after the date of this press release.
